DK1817058T3 - Sammensætning til anvendelse til forbedring af leverclearance af xenobiotiske stoffer hos et dyr - Google Patents
Sammensætning til anvendelse til forbedring af leverclearance af xenobiotiske stoffer hos et dyr Download PDFInfo
- Publication number
- DK1817058T3 DK1817058T3 DK05852254.1T DK05852254T DK1817058T3 DK 1817058 T3 DK1817058 T3 DK 1817058T3 DK 05852254 T DK05852254 T DK 05852254T DK 1817058 T3 DK1817058 T3 DK 1817058T3
- Authority
- DK
- Denmark
- Prior art keywords
- animal
- composition
- lipoic acid
- use according
- liver
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims description 85
- 239000000203 mixture Substances 0.000 title claims description 44
- 239000002676 xenobiotic agent Substances 0.000 title claims description 28
- 230000002440 hepatic effect Effects 0.000 title 1
- 235000019136 lipoic acid Nutrition 0.000 claims description 70
- 229960002663 thioctic acid Drugs 0.000 claims description 70
- 210000004185 liver Anatomy 0.000 claims description 40
- 235000005911 diet Nutrition 0.000 claims description 18
- 230000037213 diet Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 10
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 65
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 22
- 230000002034 xenobiotic effect Effects 0.000 description 22
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 235000013305 food Nutrition 0.000 description 15
- 229960003180 glutathione Drugs 0.000 description 11
- 108010024636 Glutathione Proteins 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 5
- 241000282465 Canis Species 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000006053 animal diet Substances 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010019670 Hepatic function abnormal Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000219315 Spinacia Species 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229960001734 sulfobromophthalein Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SHMXLCRUTGTGGS-UHFFFAOYSA-N dithiolane-3-carboxylic acid Chemical compound OC(=O)C1CCSS1 SHMXLCRUTGTGGS-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010419 pet care Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021413 well-balanced diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Sammensætning omfattende liponsyre til anvendelse ved forbedring af leverclearance af xenobiotiske stoffer hos et dyr, hvor anvendelsen omfatter at fodre dyret med sammensætningen.
2. Sammensætning til anvendelse ifølge krav 1, hvor anvendelsen omfatter fodring med liponsyren i mængder på mere end 5 mg om dagen.
3. Sammensætning til anvendelse ifølge krav 1, hvor anvendelsen omfatter fodring med liponsyren i mængder fra ca. 10 til ca. 1000 mg om dagen.
4. Sammensætning til anvendelse ifølge krav 1, hvor dyret er et kæledyr, og fortrinsvis hvor kæledyret er en hund.
5. Sammensætning til anvendelse ifølge krav 1, hvor liponsyren er på kapselform eller på pulverform.
6. Sammensætning til anvendelse ifølge krav 1, hvor liponsyren er på krystallinsk form.
7. Sammensætning til anvendelse ifølge krav 1, hvor liponsyren er en del af dyrets daglige kost, og fortrinsvis hvor den daglige kost omfatter liponsyre i en mængde på mere end 50 ppm på tørvægtsbasis.
8. Sammensætning ifølge krav 1, hvor liponsyren fodres til dyret i en fodersammensætning, der er egnet til at blive fortæret af dyret.
9. Sammensætning til anvendelse ifølge krav 1; hvor dyret er et ældre dyr.
10. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen omfatter: en livsbevarende mængde næringsstoffer; og mere end 50 ppm liponsyre.
11. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen er en fodersammensætning.
12. Sammensætning til anvendelse ifølge krav 11, hvor dyret er et kæledyr.
13. Sammensætning til anvendelse ifølge krav 12, hvor dyret er en hund.
14. Sammensætning til anvendelse ifølge krav 11, hvor sammensætningen er ekstruderet eller fyldt på dåser.
15. Anvendelse af en sammensætning, der omfatter liponsyre til fremstilling af et medikament til forbedring af leverclearance af xenobiotiske stoffer hos et dyr.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63097104P | 2004-11-24 | 2004-11-24 | |
| PCT/US2005/042886 WO2006058278A2 (en) | 2004-11-24 | 2005-11-23 | Methods for improving liver clearance of xenobiotic substances in an animal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1817058T3 true DK1817058T3 (da) | 2015-12-07 |
Family
ID=36498592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05852254.1T DK1817058T3 (da) | 2004-11-24 | 2005-11-23 | Sammensætning til anvendelse til forbedring af leverclearance af xenobiotiske stoffer hos et dyr |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080038323A1 (da) |
| EP (1) | EP1817058B1 (da) |
| JP (1) | JP5785355B2 (da) |
| CN (2) | CN104055764A (da) |
| AU (1) | AU2005309435B2 (da) |
| BR (1) | BRPI0518580A2 (da) |
| CA (1) | CA2588709C (da) |
| DK (1) | DK1817058T3 (da) |
| ES (1) | ES2550952T3 (da) |
| RU (1) | RU2432159C2 (da) |
| WO (1) | WO2006058278A2 (da) |
| ZA (1) | ZA200705148B (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020076470A1 (en) | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US8669282B2 (en) | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US20090156658A1 (en) * | 2000-10-31 | 2009-06-18 | Hill's Pet Nutrition, Inc. | Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| EP1817022B1 (en) * | 2004-11-24 | 2018-04-25 | Hill's Pet Nutrition, Inc. | Methods for increasing the immune response in an animal |
| RU2354136C1 (ru) | 2004-12-29 | 2009-05-10 | Хилл`С Пет Ньютришн, Инк. | Способ ингибирования ухудшения обучаемости и/или памяти у животных |
| US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| CA2592844C (en) * | 2004-12-30 | 2012-10-09 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| EP1906912B1 (en) | 2005-07-14 | 2012-08-15 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
| AU2009270712B2 (en) * | 2008-07-18 | 2013-02-21 | Hill's Pet Nutrition, Inc. | Method for enhancing the quality of life of a senior animal |
| CN105724811A (zh) * | 2008-12-16 | 2016-07-06 | 希尔氏宠物营养品公司 | 用于抑制陪伴动物的组胺路径的含抗氧化剂的食品组合物 |
| EP2653161B1 (en) | 2008-12-30 | 2015-10-07 | Hill's Pet Nutrition, Inc. | Use of lipoic acid for maintaining or increasing bone mineral density in companion animals |
| BR112012000790A2 (pt) * | 2009-07-14 | 2015-09-15 | Hills Pet Nutrition Inc | composição de ração para animais de estimação, bolinho de ração para animais de estimação, e, processo para preparar uma composição de ração para animais de estimação. |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980716A (en) * | 1954-06-11 | 1961-04-18 | Research Corp | Method for preparing 6, 8-dihalooctanoic esters |
| US2890716A (en) * | 1956-03-16 | 1959-06-16 | Buensod Stacey Inc | Control device |
| US3202514A (en) * | 1963-07-15 | 1965-08-24 | Gen Foods Corp | Animal food and method of making the same |
| US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
| US3946123A (en) * | 1975-03-10 | 1976-03-23 | Star-Kist Foods, Inc. | Canned pet food |
| US4053647A (en) * | 1975-12-12 | 1977-10-11 | Samuel Prussin | Pet food product and process of producing such |
| US4247562A (en) * | 1978-12-21 | 1981-01-27 | The Quaker Oats Company | Moist pet food with blood chunks and a fluid gravy system |
| EP0106341B1 (en) * | 1982-10-20 | 1989-01-11 | Takeda Chemical Industries, Ltd. | Physiologically active substance p-23924, its production and use |
| US5004624A (en) * | 1983-03-14 | 1991-04-02 | Star-Kist Foods, Inc. | Semi-moist pet food having free gravy and process for preparation thereof |
| WO1987007835A1 (en) * | 1986-06-21 | 1987-12-30 | Dainippon Ink And Chemicals, Inc. | Drug for treatment and prophylaxis of kidney and liver diseases |
| US5030458A (en) * | 1989-11-27 | 1991-07-09 | Shug Austin L | Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats |
| US4997672A (en) * | 1987-03-10 | 1991-03-05 | Virginia Commonwealth University | Salt taste enhancer |
| DE58902094D1 (de) * | 1988-01-28 | 1992-10-01 | Koeltringer Peter | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. |
| US6977167B2 (en) * | 1988-09-07 | 2005-12-20 | Martek Biosciences Corporation | Mixtures of omega-3 and omega-6 highly unsaturated fatty acids from euryhaline microorganisms |
| US4997671A (en) * | 1988-09-09 | 1991-03-05 | Nabisco Brands, Inc. | Chewy dog snacks |
| US5114704A (en) * | 1989-05-30 | 1992-05-19 | Nabisco Brands, Inc. | Raw hide having a coating containing an inorganic pyrophosphate |
| ES2115589T3 (es) * | 1989-11-09 | 1998-07-01 | Asta Medica Ag | Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa. |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5419283A (en) * | 1992-04-08 | 1995-05-30 | Ciuffo Gatto S.R.L. | Animal chew toy of starch material and degradable ethylene copolymer |
| US5569670A (en) * | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| US5624896A (en) * | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| DE4235912C2 (de) * | 1992-10-23 | 2002-12-05 | Viatris Gmbh | Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung |
| JP3347381B2 (ja) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | ペットフード |
| US5532010A (en) * | 1993-05-28 | 1996-07-02 | Nabisco, Inc. | Coated canine biscuits and preparation process |
| US5339771A (en) * | 1993-09-15 | 1994-08-23 | Axelrod Herbert R | Animal chew toy containing animal meal |
| WO1995013824A1 (en) * | 1993-11-15 | 1995-05-26 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering igf-i and igfbp-3 |
| US6458767B1 (en) * | 1994-05-04 | 2002-10-01 | The Uab Research Foundation | Use of peptides inhibitory for thrombospondin dependent TGF-β activation in the treatment of kidney disease |
| DE4427079C2 (de) * | 1994-07-30 | 2002-12-19 | Viatris Gmbh | Verfahren zur Racemisierung von Enantiomeren der alpha-Liponsäure |
| US5599835A (en) * | 1994-11-23 | 1997-02-04 | Fischer; Frederick B. | Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus |
| US5621177A (en) * | 1995-03-02 | 1997-04-15 | Yokogawa Electric Corporation | Electromagnetic flowmeter |
| US5730988A (en) * | 1995-04-20 | 1998-03-24 | Lynntech, Inc. | Nutritional supplements for improving glucose metabolism |
| US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| CA2208392C (en) * | 1996-06-21 | 2002-09-03 | University Of Guelph | Method for enriching docosahexaenoic acid in expressed milk of dairy cattle |
| US5965596A (en) * | 1997-08-12 | 1999-10-12 | Harris; Roger | Methods and compositions for increasing the anaerobic working capacity in tissue |
| WO1998018610A1 (en) * | 1996-10-28 | 1998-05-07 | Lengerich Bernhard H Van | Embedding and encapsulation of controlled release particles |
| US6232346B1 (en) * | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| US6133323A (en) * | 1997-04-09 | 2000-10-17 | The Iams Company | Process for enhancing immune response in animals using β-carotene as a dietary supplement |
| US5883083A (en) * | 1997-06-09 | 1999-03-16 | Harlmen, Inc. | Dietary supplement for alleviating behavioral problems in canines and reducing seizures in canines and felines |
| US5916912A (en) * | 1997-06-16 | 1999-06-29 | The Regents Of The University Of California | Dietary composition for enhancing metabolism and alleviating oxidative stress |
| US6039952A (en) * | 1997-10-22 | 2000-03-21 | The Iams Company | Composition and method for improving clinical signs in animals with renal disease |
| US6365623B1 (en) * | 1997-11-17 | 2002-04-02 | Nicholas V. Perricone | Treatment of acne using lipoic acid |
| DE19810336A1 (de) * | 1998-03-11 | 1999-09-23 | Asta Medica Ag | Alpha-Liponsäure mit neuartiger Modifikation |
| US6117477A (en) * | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
| US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| DE19834608A1 (de) * | 1998-07-31 | 2000-02-03 | Basf Ag | Kristallmodifikation der Liponsäure |
| US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
| US20040029175A1 (en) * | 1998-12-21 | 2004-02-12 | Comper Wayne D. | Method for kidney disease detection |
| MXPA01006404A (es) * | 1998-12-21 | 2003-06-06 | Univ Monash | Deteccion y tratamiento de enfermedad renal. |
| US6284786B1 (en) * | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| CN1352529A (zh) * | 1999-05-27 | 2002-06-05 | 艾姆斯公司 | 使用抗氧化剂的组合增强陪伴动物免疫反应的方法和产品 |
| US6365211B1 (en) * | 1999-06-18 | 2002-04-02 | The Procter & Gamble Co. | Cooking aid with reduced foaming |
| US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| IL149421A0 (en) * | 1999-11-02 | 2002-11-10 | Depomed Inc | Pharmaceutical compositions containing fed mode inducing agents |
| EP1248609A4 (en) * | 1999-11-03 | 2007-08-01 | Juvenon Inc | METHOD FOR TREATING THE GOOD MEMORY TROUBLESHOOTING |
| US6379727B1 (en) * | 1999-12-29 | 2002-04-30 | John F. Addy | Flavoring system for pet foods |
| US20030060503A1 (en) * | 2000-01-25 | 2003-03-27 | Juvenon, Inc. | Nutritional supplements for mature pets |
| JP2003521256A (ja) | 2000-02-01 | 2003-07-15 | マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション | 無脂肪筋量及び筋力を増強するためのαリポ酸含有食物補充物質 |
| JP4487376B2 (ja) * | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| AU2001292586A1 (en) * | 2000-09-07 | 2002-03-22 | University Of Maryland Biotechnology Institute | Use of arachidonic acid for enhanced culturing of fish larvae and broodstock |
| US6784159B2 (en) * | 2000-09-29 | 2004-08-31 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Triterpene saponins from soybeans for treating kidney disease |
| US6277842B1 (en) * | 2000-10-17 | 2001-08-21 | James Alexander Carthron | Dietary supplemental method for fat and weight reduction |
| US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US20020076470A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US20090156658A1 (en) * | 2000-10-31 | 2009-06-18 | Hill's Pet Nutrition, Inc. | Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals |
| US20020115710A1 (en) * | 2000-10-31 | 2002-08-22 | Zicker Steven Curtis | Composition and method |
| JP2004514686A (ja) * | 2000-10-31 | 2004-05-20 | コルゲート・パーモリブ・カンパニー | 組成物と方法 |
| US8669282B2 (en) * | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US20020052402A1 (en) * | 2000-10-31 | 2002-05-02 | Colgate-Palmolive Company | Composition and method |
| ES2311482T3 (es) * | 2000-12-29 | 2009-02-16 | Martin Francis Gannon | Producto alimenticio para animales. |
| EA006429B1 (ru) * | 2001-03-09 | 2005-12-29 | Сосьете Де Продюи Нестле С.А. | Композиция для предупреждения или восстановления возрастных функциональных дефицитов у млекопитающих и способ ее применения |
| CA2446027C (en) * | 2001-05-14 | 2009-04-28 | Martek Biosciences Corporation | A method of improving the flavor, tenderness and overall consumer acceptability of poultry meat |
| US6596762B2 (en) * | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| US6596768B2 (en) * | 2001-05-22 | 2003-07-22 | Church & Dwight Co., Inc. | Unsaturated lipid-enriched feedstock for ruminants |
| DE10125882B4 (de) * | 2001-05-28 | 2007-03-29 | Esparma Gmbh | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus |
| US6902739B2 (en) * | 2001-07-23 | 2005-06-07 | Nutracea | Methods for treating joint inflammation, pain, and loss of mobility |
| GB0119052D0 (en) * | 2001-08-03 | 2001-09-26 | Mars Uk Ltd | Foodstuff |
| DE10151764A1 (de) * | 2001-10-19 | 2003-05-08 | Basf Ag | Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| US6733793B2 (en) * | 2002-06-04 | 2004-05-11 | Metaproteomics, Llc | Oral composition with insulin-like activities and methods of use |
| US8841344B2 (en) * | 2002-10-03 | 2014-09-23 | Hill's Pet Nutrition, Inc. | Method of using omega-3 fatty acids |
| CA2525560A1 (en) * | 2003-05-13 | 2004-11-25 | The Regents Of The University Of Colorado | Diagnostic and therapeutic treatments related to mitochondrial disorders |
| US7202270B2 (en) * | 2003-06-20 | 2007-04-10 | Sami Labs Limited | Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses |
| US7078064B2 (en) * | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| US20060002985A1 (en) * | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| US8168161B2 (en) * | 2004-12-22 | 2012-05-01 | Hill's Pet Nutrition, Inc. | Method to promote oral health in companion animals |
| RU2354136C1 (ru) * | 2004-12-29 | 2009-05-10 | Хилл`С Пет Ньютришн, Инк. | Способ ингибирования ухудшения обучаемости и/или памяти у животных |
| EP1906912B1 (en) * | 2005-07-14 | 2012-08-15 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
| EP1928453B1 (en) * | 2005-08-17 | 2017-10-18 | Hill's Pet Nutrition, Inc. | Compositions and their use for the prevention and treatment of kidney disease |
-
2005
- 2005-11-23 CN CN201410319876.2A patent/CN104055764A/zh active Pending
- 2005-11-23 JP JP2007543562A patent/JP5785355B2/ja active Active
- 2005-11-23 ES ES05852254.1T patent/ES2550952T3/es active Active
- 2005-11-23 RU RU2007123601/15A patent/RU2432159C2/ru not_active IP Right Cessation
- 2005-11-23 BR BRPI0518580-7A patent/BRPI0518580A2/pt not_active Application Discontinuation
- 2005-11-23 AU AU2005309435A patent/AU2005309435B2/en not_active Ceased
- 2005-11-23 WO PCT/US2005/042886 patent/WO2006058278A2/en active Application Filing
- 2005-11-23 EP EP05852254.1A patent/EP1817058B1/en active Active
- 2005-11-23 DK DK05852254.1T patent/DK1817058T3/da active
- 2005-11-23 CN CNA2005800471085A patent/CN101107012A/zh active Pending
- 2005-11-23 CA CA2588709A patent/CA2588709C/en not_active Expired - Fee Related
-
2007
- 2007-05-24 US US11/753,404 patent/US20080038323A1/en not_active Abandoned
- 2007-06-21 ZA ZA200705148A patent/ZA200705148B/xx unknown
-
2009
- 2009-07-16 US US12/504,068 patent/US20100076064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100076064A1 (en) | 2010-03-25 |
| RU2007123601A (ru) | 2008-12-27 |
| US20080038323A1 (en) | 2008-02-14 |
| AU2005309435A1 (en) | 2006-06-01 |
| JP5785355B2 (ja) | 2015-09-30 |
| BRPI0518580A2 (pt) | 2008-11-25 |
| EP1817058B1 (en) | 2015-09-02 |
| WO2006058278A3 (en) | 2007-02-01 |
| AU2005309435B2 (en) | 2011-09-22 |
| RU2432159C2 (ru) | 2011-10-27 |
| ES2550952T3 (es) | 2015-11-13 |
| EP1817058A4 (en) | 2012-07-11 |
| JP2008521408A (ja) | 2008-06-26 |
| CA2588709C (en) | 2015-07-14 |
| CA2588709A1 (en) | 2006-06-01 |
| CN104055764A (zh) | 2014-09-24 |
| CN101107012A (zh) | 2008-01-16 |
| EP1817058A2 (en) | 2007-08-15 |
| WO2006058278A2 (en) | 2006-06-01 |
| ZA200705148B (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1817058T3 (da) | Sammensætning til anvendelse til forbedring af leverclearance af xenobiotiske stoffer hos et dyr | |
| CA2588708C (en) | Use of lipoic acid to improve immune response by increased natural killer cell activity | |
| CA2644848C (en) | Compositions and methods for enhancing the antioxidant status of animals | |
| AU2006305808B2 (en) | Compositions and methods for increasing lean muscle mass and/or reducing fat gain | |
| DK2387325T3 (da) | Fremgangsmåder til forbedring af lever- og immunfunktion hos et dyr | |
| US9596870B2 (en) | Compositions and methods for enhancing exercise performance |